Exelixis | EXEL - Selling And Administration Expenses


Exelixis reported $147.63M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 148.57M 12.22M Jun/2026
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Amgen USD 1.72B 134M Jun/2026
AstraZeneca USD 5.8B 735M Jun/2026
Bayer EUR 3.96B 267M Jun/2026
BioMarin Pharmaceutical USD 395.55M 137.27M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Cytokinetics USD 104.4M 499K Jun/2026
Eisai JPY 114.83B 4.71B Jun/2026
Eli Lilly USD 3.43B 496M Jun/2026
Exelixis USD 147.63M 8.03M Jun/2026
Genmab DKK 205M 39M Jun/2026
Glaxosmithkline GBP 2.12B 1.44B Mar/2026
Incyte USD 351.73M 23.64M Jun/2026
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
MacroGenics USD 9.71M 1.77M Mar/2026
Merck USD 2.89B 219M Jun/2026
Moderna USD 216M 43M Jun/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
Novartis USD 3.24B 101M Jun/2026
Pfizer USD 3.41B 496M Jun/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Sanofi EUR 2.49B 252M Mar/2026
Takeda JPY 286.51B 5.48B Jun/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Xencor USD 77.54M 4.59M Jun/2026